Betamethasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Betamethasone: From Autoimmune and Inflammatory Conditions to Alopecia Areata
One-Sentence Summary
Betamethasone is a potent glucocorticoid, originally used for autoimmune and inflammatory conditions such as Crohn disease, adrenocortical insufficiency, eosinophilic pneumonia and skin conditions such as tinea pedis and exanthem. The TxGNN model predicts it may be effective for alopecia areata, with 6 clinical trials (1 completed Phase 2 trial testing betamethasone directly) and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, Crohn disease, adrenocortical insufficiency, eosinophilic pneumonia, acute lymphoblastic leukaemia and others (the approved indication text for the Singapore licences is not available) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known glucocorticoid pharmacology, betamethasone is a potent corticosteroid with anti-inflammatory and immunosuppressive activity. Its efficacy in autoimmune and inflammatory diseases is well established.
Alopecia areata is a T-cell-mediated autoimmune disease in which the immune privilege of the hair follicle collapses. Corticosteroids suppress the inflammatory infiltrate around the follicle, so the mechanism is consistent with betamethasone's established use in autoimmune conditions.
Several delivery routes have been studied in alopecia areata: topical, intralesional, microneedle-delivered and oral mini-pulse regimens. This breadth of use supports the plausibility of the model's prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06786689 | Phase 2 | Completed | 60 | Weekly azathioprine pulse vs oral betamethasone mini-pulse in moderate to severe alopecia areata |
| NCT02350023 | Phase 4 | Completed | 50 | Topical latanoprost vs topical corticosteroid (likely betamethasone) in localised alopecia areata |
| NCT05803070 | N/A | Unknown | 59 | Topical cetirizine 1% vs topical betamethasone valerate 0.1% in localised alopecia areata |
| NCT06087796 | Phase 1 | Unknown | 60 | Topical pentoxifylline and metformin vs betamethasone valerate 0.1% cream in patchy alopecia areata |
| NCT07696585 | N/A | Not yet recruiting | 60 | Topical metformin 30%, simvastatin 2% and betamethasone valerate 0.1% in patchy alopecia areata |
| NCT04207931 | Phase 4 | Recruiting | 250 | Treatment outcomes in central centrifugal cicatricial alopecia, a different (scarring) condition and only indirectly relevant |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37870096 | 2023 | Meta-analysis | Cochrane Database Syst Rev | Network meta-analysis of treatments for alopecia areata |
| 39393548 | 2025 | RCT | J Am Acad Dermatol | Microneedle transdermal delivery of compound betamethasone, as a less painful alternative to intralesional injection |
| 36257912 | 2022 | RCT | Dermatol Ther | Blinded six-group trial of latanoprost vs minoxidil, betamethasone and combinations |
| 34400956 | 2021 | RCT | Iran J Pharm Res | Oral pulse betamethasone, methotrexate and their combination vs placebo in severe alopecia areata (36 patients) |
| 32594786 | 2022 | RCT | J Dermatolog Treat | Within-patient comparison of intralesional betamethasone vs triamcinolone in localised alopecia areata |
| 40510104 | 2025 | RCT | Cureus | Oral cyclosporine vs oral betamethasone minipulse (60 patients) |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Efficacy, relapse and side effects of corticosteroid pulse therapy in alopecia areata |
| 36461625 | 2023 | Review | Pediatr Dermatol | Dosing and administration of pulse corticosteroids in children with alopecia areata |
| 40519428 | 2025 | Clinical study | Cureus | Efficacy and safety of oral betamethasone mini-pulses in moderate to severe alopecia areata |
| 38623137 | 2024 | Comparative study | Cureus | Topical betamethasone dipropionate vs topical minoxidil |
Singapore Market Information
All 20 licences are valid single-ingredient products. The approved indication text is not available for them. The licences listed are a selection of the main products (topical dosage forms).
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04025P | Diprosone Cream 0.05% | Cream | Not available |
| SIN07714P | Betnovate Scalp Application 0.1% w/w | Solution | Not available |
| SIN03842P | Diprocel Ointment 0.05% | Ointment | Not available |
| SIN09789P | Dermasone Scalp Lotion 0.1% | Lotion | Not available |
| SIN08515P | Temprosone Gel 0.05% | Gel | Not available |
Safety Considerations
- Contraindications (from knowledge-graph associations, not label text): hypertension, congestive heart failure, epilepsy, hyperglycaemia, herpes simplex virus keratitis, measles, hypopituitarism and growth hormone deficiency conditions, and urea cycle disorders (e.g. citrullinemia, hyperargininemia).
- Drug Interactions: 100 interactions were identified. Notable examples are adalimumab (Major) and several Moderate interactions, including isotretinoin, ketorolac, ibuprofen, nifedipine, acarbose, zidovudine, fluvoxamine, fosamprenavir, ethinylestradiol, aldesleukin, alemtuzumab and tetanus toxoid vaccine. Formoterol and salbutamol interactions are Minor.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 2 trial tests oral betamethasone mini-pulse directly in alopecia areata, and several randomised trials cover topical, intralesional, microneedle and oral regimens. Evidence is sufficient for further evaluation. However, most trials use betamethasone as a comparator, they are small, and the Singapore licences are all for topical products, so oral and intralesional use would need a separate regulatory pathway.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, which are required before safety screening
- Detailed mechanism of action data
- Results and efficacy data from the completed trials, especially NCT06786689, and larger confirmatory RCTs
- Comparison against established alopecia areata treatments, including those in the Cochrane network meta-analysis
- A route and formulation decision (topical, intralesional, microneedle or oral mini-pulse) with a safety monitoring plan covering systemic corticosteroid effects and the interaction with adalimumab
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.